 |
|
|
| |
Excess mortality risk among hepatitis C patients
after being ''cured'' in the interferon-free era:
results from three population-based cohorts
|
| |
| |
EASL 2022 June 22-26 London
Dr Victoria Hamill
Medical Statistician at Glasgow Caledonian University and Public Health Scotland
Hamill V, Wong S, Benselin J, Krajden M, Hayes PC, Mutimer D, Yu A, Dillon JF, Gelson W, Velásquez García HA, Johnson P, Barclay ST, Alvarez M, Toyoda H, Agarwal K, Fraser A, Bartlett S, Aldersley M, Bathgate A, Binka M, Richardson, Morling JR, Ryder SD, MacDonald D, Hutchinson S, Barnes E, Guha NI, Irving WL, Janjua NZ, Innes H
Clearly one of the key causes of death is that many people treated with DAAs who achieve cure but had cirrhosis before treatment are NOT receiving proper & recommended surveillance, followup with every 6 months ultrasound or MRI as recommended by every body - AASLD, EASL. In the rush to treat everyone this is getting lost. Consequently many people wo had cirrhosis before treatment and are supposed to have surveillance after cure are nt receiving that. This is reflected in the high rates f people who use drugs who do not come back to see doctors after their cure at week 24 or even sooner, they think they are in the sea, and its also a sign that some of those treating HCV may no be shown adequate attention to surveillance. Jules
|
| |
|
|
|
|
|
